NCT01407874已完成2 期
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 主要终点
- To evaluate the overall safety and tolerability of ulodesine when combined with allopurinol in subjects with moderate renal insufficiency by assessment of percent change from baseline in CD4+ lymphocytes at Day 85.
研究概览
简要总结
To evaluate the overall safety and tolerability of ulodesine when combined with allopurinol in subjects with moderate renal insufficiency.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 69 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 to < 70 years
- •Have read and signed the Informed Consent Form
- •Documented diagnosis of gout
- •Documented moderate renal insufficiency
- •Calculated creatinine clearance of ≥ 30 and < 60 mL/min
- •Willing and able to take allopurinol 200 mg every day for the duration of the Treatment
- •Female participants must be sexually abstinent for 4 weeks prior to Day 1 and continue abstinence for 4 weeks after completion of study drug, surgically sterile, postmenopausal,use oral contraceptives for three months prior to study drug dosing through 4 weeks after completion of study drug, an intrauterine device for 8 weeks prior to study drug dosing through 4 weeks after completion of study drug,double barrier contraception method for 4 weeks prior to study drug dosing through 4 weeks after completion of study drug administration
- •Male participants must be sexually abstinent for 4 weeks prior to Day 1 and continue abstinence through 90 days after completion of study drug, be > 1 year postvasectomy, agree to use a condom with spermicide from the start of study drug dosing through 90 days after completion of study drug.
- •Willing and able to provide authorization for the use and disclosure of personal health information in accordance with Health Insurance Portability and Accountability Act (HIPAA)
排除标准
- •Unable to tolerate allopurinol 200 mg every day
- •Prior randomization in a clinical study with BCX4208
- •Unstable cardiac disease such as: unstable angina, symptomatic arrhythmia, signs or symptoms compatible with NYHA Class III or Class IV functional status for congestive heart failure or angina, history of long QT syndrome, or QTc interval < 350 msec or > 475 msec
- •Poorly controlled hypertension
- •History of severe renal insufficiency
- •Alanine aminotransferase or aspartate aminotransferase values > 2.0 x upper limit of normal
- •CD4+ cell counts by flow cytometry < 500 cells/mm3
- •Hemoglobin < 10 g/dL or > 18 g/dL (males) or < 10 g/dL or > 17 g/dL (females)
- •White blood cell count < 3.7 x 109/L or > 11 x 109/L
- •Female subjects who are pregnant, breastfeeding, or planning a pregnancy within the next 4 months
- •Positive serology for hepatitis B surface antigen or hepatitis C antibody or HIV type 1
- •Immunocompromised due to illness or organ transplant
- •Use of systemic immunosuppressive medications or disease-modifying antirheumatic drugs
- •Use of azathioprine or 6-mercatopurine within 14 days of first dose of allopurinol
- •Use of hydrochlorothiazide in doses > 50 mg per day
- •Planned use of herbal or dietary supplements
- •Recipient of any live or attenuated vaccine within 6 weeks of Screening
- •Planned use of uric acid-lowering drugs other than allopurinol
- •Use of systemic corticosteroids within 4 weeks prior to Day 1
- •Use of any investigational drug within 30 days prior to signing the ICF
- •History of clinically significant and relevant drug allergies
- •History of chronic or recurrent infections
- •History of any type of cancer not successfully treated or in full remission for 12 months prior to Screening
- •History of alcohol or drug abuse within the year prior to the signing of the ICF, or current evidence of substance dependence or abuse
- •Use of other prohibited medications within the timeframes specified in the protocol
- •Other medical conditions which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject
研究组 & 干预措施
Placebo
Experimental
Placebo + Allopurinol 200mg
干预措施: Placebo (Drug)
Ulodesine (BCX4208) 5mg
Experimental
BCX4208 5mg + Allopurinol 200 mg
干预措施: Ulodesine (BCX4208) 5 mg (Drug)
Ulodesine (BCX4208) 10mg
Experimental
BCX4208 10mg + Allopurinol 200mg
干预措施: Ulodesine (BCX4208) 10 mg (Drug)
结局指标
主要结局
To evaluate the overall safety and tolerability of ulodesine when combined with allopurinol in subjects with moderate renal insufficiency by assessment of percent change from baseline in CD4+ lymphocytes at Day 85.
时间窗: 85 days
Level of CD4+ lymphocytes to be measured at Day 85 compared to baseline.
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to AllopurinolGoutArthritisJoint DiseaseHyperuricemiaNCT01265264BioCryst Pharmaceuticals279
终止
3 期
Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)Primary Biliary CirrhosisNCT00746486Dr. Falk Pharma GmbH62
已完成
4 期
Microalbuminuria and Allopurinol in Type 1 DiabetesType 1 DiabetesDiabetic NephropathyNCT02829177Peter Rossing30
终止
2 期
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.Cirrhosis, LiverAscites HepaticNCT04311489University of Aarhus17
招募中
2 期
Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic CancerPancreatic NeoplasmsNCT05795920Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine92